Apellis Pharmaceuticals Inc., a biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through the inhibition of the complement system, has initiated its PEGASUS Phase 3 clinical trial assessing the safety and efficacy of APL-2, a novel inhibitor of complement factor C3, in patients with PNH compared to eculizumab.
According to a company news release, PEGASUS is a 70-patient, randomized, head-to-head study comparing APL-2 monotherapy to eculizumab monotherapy in patients currently on treatment with eculizumab who have a hemoglobin level <10.5 g/dL, regardless of eculizumab dose or transfusion history. APL-2 is being investigated with the goal of improving anemia and transfusion dependency in patients with PNH.
Currently, the PEGASUS Phase 3 trial is recruiting PNH patients in the U.S., but the Canadian Association of PNH Patients has learned from Apellis that the company hopes to add other clinical trial centres in the near future, including in Canada.
For more information on the PEGASUS Phase 3 clinical trial, visit ClinicalTrials.gov here.